Authors' response to the letter "Temozolomide-Capecitabine (TemCap) chemotherapy for Neuroendocrine Neoplasms (NENs): the dilemma of treatment duration" by Lamarca et al. regarding the original manuscript "Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms."
n/a, this is a response to a letter to the editor.